Scientists are closing in on a deceptively simple idea with radical implications: that a single protein signal in the blood ...

Immune protection fades with time, and much of that decline traces back to the thymus. This small organ, located in front of the heart, trains new T cells and releases signals that help them survive.

The window for CureVac investors to decide on the proposed acquisition by BioNTech is rapidly closing. The tender offer is entering its conclusive stage, mar ...

RNA-based therapeutics are transforming medicine, but scaling production efficiently remains a challenge, particularly the cost-intensive in vitro transcription (IVT) step. Join this webinar to ...

In a Phase 3 trial of more than 18,000 volunteers across three countries, an mRNA influenza vaccine from Pfizer has outperformed standard seasonal flu shots by 34.5%. It's yet another sign that this ...

Flu vaccines that take a page from the COVID-19 vaccine platform are making progress in clinical trials. In a phase 3 trial, Pfizer’s mRNA flu vaccine outperformed a traditional vaccine, researchers ...

Nov 19 (Reuters) - Moderna (MRNA.O), opens new tab said on Wednesday it would now operate full end-to-end manufacturing for its mRNA medicines in the U.S., marking a major step in strengthening the ...

Researchers at MIT have just developed a new lipid nanoparticle that super-enhances the effectiveness of the mRNA vaccine in mice to a hundred times its stand-alone effectiveness, thus offering ...

COVID-19 mRNA vaccines create enough of an immunity boost to extend survival in certain types of lung and skin cancers, an analysis of more than 1,000 patient files showed. The scientific journal ...

Hematologic malignancies encompass a group of cancers that stem from lymphohematopoietic system. These malignancies include such categories as: acute and chronic leukemias, lymphomas, multiple ...

Vaccines that resemble viruses generally produce a stronger immune response, while mRNA versions are much quicker and cheaper to make. Now we are getting the best of both worlds, in the form of mRNA ...

As BioNTech works to establish a production footprint for mRNA vaccines in Africa, two EU groups have offered financial backing to the company's efforts. The European Commission pledged a 35 million ...